DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
23,900
-700 (-2.85%)
Apr 30, 2026, 3:30 PM KST
Market Cap1.11T +67.6%
Revenue (ttm)926.88B +14.1%
Net Income66.02B +7.8%
EPS1,475.00 +7.8%
Shares Out45.11M
PE Ratio16.68
Forward PE13.06
Dividend200.00 (0.80%)
Ex-Dividend DateDec 29, 2025
Volume631,510
Average Volume810,551
Open24,450
Previous Close24,600
Day's Range23,700 - 24,550
52-Week Range15,030 - 31,250
Beta0.09
RSI46.86
Earnings DateMay 15, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Sector Healthcare
Founded 1968
Employees 1,233
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements